Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy

an antiallergic agent and allergy technology, applied in the field of antiallergic agents, can solve the problems of side effects, no fundamental therapeutic agent has been found for specifically reducing ige antibody

Inactive Publication Date: 2005-09-29
CALPIS
View PDF18 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0073] Each of the lactic acid bacterial strains shown in Table 1 was precultured in MRS medium overnight at 37° C., and the cells were harvested by centrifugation at 3000 rpm for 10 minutes. 9% (W/V) reconstituted skim milk (containing 0.1% (W/V) yeast extract (manufactured by DIFCO)) was fermented with the collected cells at 37° C. until the milk was coagulated. After the fermentation, the total ce

Problems solved by technology

However, both of these agents merely provide symptomatic therapy, and steroids inhibit the overall immune response, resulting in side effects.
Alternatively, agents for inhibiting release of chemical medi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy
  • Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy
  • Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy

Examples

Experimental program
Comparison scheme
Effect test

example 1

(Preparation of IgE-elevated Mice)

[0064] Male BALB / c mice were obtained from Charles River Japan, and raised under free access to CE-2 (CLEA Japan, Inc.) as a feed. 10 μg of ovalbumin (abbreviated as OVA hereinbelow, manufactured by SIGMA CHEMICAL CO.) and 2 mg of aluminum hydroxide (WAKO PURE CHEMICAL INDUSTRIES, LTD.) as an adjuvant were suspended in 300 μl of saline. Ten of the above mice at six weeks old were injected intraperitoneally with this suspension on the first day of sensitization and on day 4 for primary sensitization. For secondary sensitization, the nose of each mouse was soaked in an OVA antigen solution containing 25 mg OVA / ml of saline for three seconds, and this soaking operation was repeated three times as one cycle. Two cycles of soaking operation was performed per day, and the daily soaking was performed from day 10 to day 16 to prepare IgE-elevated mice.

[0065] Blood samples were obtained from the ophthalmic veins of the IgE-elevated mice on the first day a...

example 2

(Comparison in Effect of Various Lactic Acid Bacteria)

[0073] Each of the lactic acid bacterial strains shown in Table 1 was precultured in MRS medium overnight at 37° C., and the cells were harvested by centrifugation at 3000 rpm for 10 minutes. 9% (W / V) reconstituted skim milk (containing 0.1% (W / V) yeast extract (manufactured by DIFCO)) was fermented with the collected cells at 37° C. until the milk was coagulated. After the fermentation, the total cell count of each fermented milk was measured. The results are shown in Table 1.

TABLE 1Total cellcountStrain(cells / ml)Lactobacillus acidophilus CL92 (BP-4981)1.9 × 108Lactobacillus bulgaricus CP18121.5 × 108Lactobacillus fermentum CP345.3 × 108Lactobacillus helveticus CP7902.4 × 108Lactobacillus johnsonii CP25512.7 × 108Lactobacillus plantarum CP21725.9 × 108Lactobacillus rhamnosus ATCC531031.0 × 108

[0074] Next, IgE-elevated mice were prepared in the same way as in Example 1, and the blood OVA-IgE was measured on day 18 of sensitiz...

example 3

[0076] The procedure in Example 2 was followed except that the lactic acid bacterial strains shown in Table 2 were used. The results of measurement of the total cell count in each fermented milk are shown in Table 2. The results of measurement of the blood OVA-IgE are shown in FIG. 3.

TABLE 2Total cellcountStrain(cells / ml)Lactobacillus acidophilus CL0062 (BP-4980)4.40 × 108Lactobacillus gasseri CP22094.30 × 108Lactobacillus reuteri ATCC232729.60 × 108Bifidobacterium breve CP24251.30 × 108

[0077] As shown in FIG. 3, in the group of mice given Lactobacillus acidophilus fermented milk, significant inhibitory effect (p<0.01) in OVA-IgE level was observed, compared to the group given non-fermented skim milk. No significant difference was observed in total IgG level in blood (not shown).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an antiallergic agent containing, as an active ingredient, lactic acid bacteria selected from the group consisting of lactic acid bacteria of the species Lactobacillus acidophilus, Lactobacillus fermentum, and combinations thereof. The antiallergic agent is capable of improving allergic diathesis by reducing the IgE level, which is contributive to development of Type I allergy, and is easy to take and highly safe. The present invention also provides use of the antiallergic agent for reducing allergy, and a method for reducing allergy using the antiallergic agent.

Description

FIELD OF ART [0001] The present invention relates antiallergic agents. The invention also relates to use of the antiallergic agents for reducing allergy, and a method for reducing allergy. BACKGROUND ART [0002] Allergic patients have been increasing in number every year in many countries including Japan, and high incident of allergic adults, one out of three in Japan, is reported. Allergic diseases are categorized into four types, type I to IV, depending on their mechanism of action. Some kinds of allergic rhinitis such as pollinosis, bronchial asthma, and atopic dermatitis are Type I immunoglobulin E (IgE)-mediated allergy, wherein increase in antigen-specific IgE level in blood enhances the risk of developing allergic symptoms. [0003] The mechanism of development of Type I allergy is as follows. When an antigen, such as pollens, house dust, or mites, invades the body, an IgE antibody specific to such antigen is produced, and binds to mast cells or Fcε receptors on the basophil sur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/74A61K35/747A61P11/02A61P11/06A61P17/00A61P37/08A61P43/00
CPCY10S435/854A61K35/747A61P11/02A61P11/06A61P17/00A61P37/08A61P43/00A61K47/00
Inventor YAMAMOTO, NAOUKIISHIDA, YUUBANDO, IZUKI
Owner CALPIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap